ArticleJournal of clinical medicine2025
Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study.
Omer Acar et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.